28663-68-5

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL (2E)-CHLORO(PHENYLHYDRAZONO)ACETATE is used as a synthetic intermediate for the preparation of full-substituted pyrazole derivatives. These pyrazole derivatives are known for their diverse range of biological activities, including anti-inflammatory, antifungal, and antimicrobial properties. They are also used in the development of pharmaceuticals targeting various diseases, such as cancer, diabetes, and neurological disorders.
Used in Chemical Research:
In the field of chemical research, ETHYL (2E)-CHLORO(PHENYLHYDRAZONO)ACETATE is utilized as a starting material for the synthesis of various complex organic molecules. Its unique structure allows for a wide range of reactions, enabling the creation of novel compounds with potential applications in various industries, such as agriculture, materials science, and pharmaceuticals.
Used in Material Science:
ETHYL (2E)-CHLORO(PHENYLHYDRAZONO)ACETATE can be employed in the development of new materials with specific properties, such as improved stability, enhanced reactivity, or tailored physical characteristics. These materials can be used in various applications, including coatings, adhesives, and polymers, where their unique properties can provide advantages over existing materials.

InChI:InChI=1/C10H11ClN2O2/c1-2-15-10(14)9(11)13-12-8-6-4-3-5-7-8/h3-7,12H,2H2,1H3

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 67-56-1 methanol 
• 100-34-5 benzene diazonium chloride 
• 10475-63-5 3-oxo-2-(phenylhydrazono)butyric acid ethyl ester 
• 112260-88-5 ethyl dichlorothionoacetate 
• 62-53-3 aniline 
• 609-15-4 ethyl 2-chloro-3-oxo-butyrate 
• 105-39-5 chloroacetic acid ethyl ester 
• 80447-71-8 phenylhydrazone of ethyl ester of glyoxalic acid 
• 100-63-0 phenylhydrazine 
• 127-09-3 sodium acetate 
• 7782-50-5 chlorine 
• 128100-08-3 (Phenyl-ONN-azoxy)-acetic acid ethyl ester 
• 938-81-8 N-nitrosoacetanilide 

Downstream Products

• 36999-43-6 ethyl α-amino-α-(phenylhydrazono)glyoxylate 
• 61349-70-0 5,5-di-morpholin-4-yl-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester 
• 56885-96-2 5-(2-oxo-2-p-tolyl-ethylidene)-4-phenyl-4,5-dihydro-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester 
• 39143-38-9 6-tert-butyl-3-ethoxycarbonyl-1,4,4-triphenyl-1,4-dihydro-[1,2,4]diazaphosphininium; chloride 
• 56456-85-0 1,4-Dihydro-1-phenyl-indeno[1,2-c]pyrazole-3-carboxylic acid,ethyl ester 
• 56885-92-8 5-(2-oxo-2-phenyl-ethylidene)-4-phenyl-4,5-dihydro-[1,3,4]thiadiazole-2-carboxylic acid ethyl ester 
• 56886-03-4 2-(2-oxo-2-phenyl-ethylidene)-3-phenyl-thiazolidine-4,5-dione 5-phenylhydrazone 
• 87287-58-9 6-(Phenyl-hydrazono)-1H-imidazo[1,2-b][1,2,4]triazol-5-one 
• 88860-92-8 1-phenyl-3-ethoxycarbonyl-4-acetylpyrazole 
• 86955-91-1 Ethyl 1-phenyl-4-(trimethylsilyl)pyrazole-3-carboxylate 
• 86955-92-2 3-Carboethoxy-4-carbomethoxy-1-phenyl-2-pyrazoline 
• 86955-93-3 3-Carboethoxy-4-carbomethoxy-1-phenyl-4-(trimethylsilyl)-2-pyrazoline 
• 144309-52-4 (4S,5R)-5-Benzoyl-1-phenyl-4-p-tolyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester 
• 144309-53-5 (4S,5R)-5-Benzoyl-4-(4-chloro-phenyl)-1-phenyl-4,5-dihydro-1H-pyrazole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists

Chemokine receptor 2 (CXCR2) is the receptor of glutamic acid–leucine–arginine sequence-contained chemokines CXCs (ELR+ CXCs). In recent years, CXCR2-target treatment strategy has come a long way in cancer therapy. CXCR2 antagonists could block

PYRAZOLOPYRIDAZINE DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

The present invention is a pyrazolopyridazine derivative. A pharmaceutical composition for preventing or treating cancer contains the pyrazolopyridazin derivative compound Hsp90 according to the present invention as an active ingredient, which can be used as Hsp90 a pharmaceutical composition for preventing or treating Hsp90-related diseases such as melanoma, brain tumor, breast cancer, lung cancer and the like. (by machine translation)

Pyrazole-4-Carboxamide (YW2065): A Therapeutic Candidate for Colorectal Cancer via Dual Activities of Wnt/β-Catenin Signaling Inhibition and AMP-Activated Protein Kinase (AMPK) Activation

Dysregulation of the Wnt/β-catenin signaling pathway has been widely recognized as a pathogenic mechanism for colorectal cancer (CRC). Although numerous Wnt inhibitors have been developed, they commonly suffer from toxicity and unintended effects. Moreover, concerns have been raised in targeting this pathway because of its critical roles in maintaining stem cells and regenerating tissues and organs. On the basis of the anthelmintic drug pyrvinium and previous lead FX1128, we have developed a compound YW2065 (1c) which demonstrated excellent anti-CRC effects in vitro and in vivo. YW2065 achieves its inhibitory activity for Wnt signaling by stabilizing Axin-1, a scaffolding protein that regulates proteasome degradation of β-catenin. Simultaneously, YW2065 also led to the activation of the tumor suppressor AMPK, providing an additional anticancer mechanism. In addition, YW2065 showed favorable pharmacokinetic properties without obvious toxicity. The anti-CRC effect of YW2065 was highlighted by its promising efficacy in a mice xenograft model.

Discovery and Development of a Series of Pyrazolo[3,4- d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design

Alterations of fibroblast growth factor receptors (FGFRs) play key roles in numerous cancer progression and development, which makes FGFRs attractive targets in the cancer therapy. In the present study, based on a newly devised FGFR target-specific scorin

5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a co

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE

Compounds and compositions are provided as inhibitors of the Wnt/β-catenin pathway for the treatment of diseases that implicate the same.

Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors

A series of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety were synthesized and evaluated for their in?vitro cytotoxic activity against four cancer cell lines (HT-29, H460, A549 and MKN-45). Most of the compounds exhibited moderate-to-significant cytotoxicity. Compounds 33, 37, 39, 44, 46, 47, 53, 55, 61, 64 and 66 were further examined for their inhibitory activity against c-Met kinase. The most promising compound 47 (with c-Met IC50value of 1.57?nM) showed remarkable cytotoxicity against HT-29, H460, A549 and MKN-45?cell lines with IC50values of 0.08?μM, 0.14?μM, 0.11?μM and 0.031?μM, respectively, and thus it was 1.1- to 2.3- fold more potent than foretinib. Their preliminary structure-activity relationships (SARs) studies indicate that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity.

Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors

A new series of 7-aminopyrazolo[4,3-d]pyrimidine derivatives (1-31) were synthesized to evaluate some structural modifications at the 2- and 5-positions aimed at shifting affinity towards the human (h) A2A adenosine receptor (AR) or both hA2A and hA1 ARs. The most active compounds were those featured by a 2-furyl or 5-methylfuran-2-yl moiety at position 5, combined with a benzyl or a substituted-benzyl group at position 2. Several of these derivatives (22-31) displayed nanomolar affinity for the hA2A AR (Ki = 3.62-57 nM) and slightly lower for the hA1 ARs, thus showing different degrees (3-22 fold) of hA2A versus hA1 selectivity. In particular, the 2-(2-methoxybenzyl)-5-(5-methylfuran-2-yl) derivative 25 possessed the highest hA2A and hA1 AR affinities (Ki = 3.62 nM and 18 nM, respectively) and behaved as potent antagonist at both these receptors (cAMP assays). Its 2-(2-hydroxybenzyl) analog 26 also showed a high affinity for the hA2A AR (Ki = 5.26 nM) and was 22-fold selective versus the hA1 subtype. Molecular docking investigations performed at the hA2A AR crystal structure and at a homology model of the hA1 AR allowed us to represent the hypothetical binding mode of our derivatives and to rationalize the observed SARs.

Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly

A major challenge in drug discovery is to develop and improve methods for targeting protein-protein interactions. Further exemplification of the REPLACE (REplacement with Partial Ligand Alternatives through Computational Enrichment) strategy for generatin